The share of pharmaceutical ETF has increased since July, and the share of 10 products has increased by more than 100 million copies

Since the second half of 2022, the enthusiasm of investors' layout of pharmaceutical ETFs has continued, and related theme funds share has increased significantly.

Choice data shows that among the 39 pharmaceutical ETFs, since the second half of 2022 (July 1-August 21, the same below), 27 funds have achieved share growth, a total of 12.847 billion copies, and 10 funds have increased share growth More than 100 million copies.

Specifically, ETF (512010) and Huabao Fund's Medical ETF (512170) share of the Yifangda Fund's share of 5.629 billion yuan has increased. By 22.189 billion, 29.977 billion. In terms of scale, these two ETFs are also the only pharmaceutical ETFs in the market with more than 10 billion yuan. The latest management scale is 10.684 billion yuan and 15.297 billion yuan, respectively.

Cathay Fund ETF (512290) and medical ETF (159828) were jointly managed by fund managers Liang Xing and Huang Yue. Since the second half of 2022, the fund share has added 682 million and 600 million copies, respectively.

Biomedical ETF (159859), Medicine and Hygiene ETF (159938), Biotechnology ETF (159837), Medical Innovation ETF (516820), Medical Devices ETF (159883), and Medicine ETF (159929) have increased by 389 million copies and 245 million. 2270 million, 174 million, 143 million, and 122 million copies. These six products are managed by Tianhong Fund, Guangfa Fund, E Fund Fund, Ping An Fund, Yongying Fund, and Huitianfu Fund.

- END -